ZURICH/BERLIN, May 14 (Reuters) - The Swiss blue-chip SMI was seen opening 0.4% lower at 9,595 points on Thursday, around 15% down from its record high earlier this year, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
The Swiss insurer on Thursday said property and casualty claims related to the coronavirus pandemic could total around $750 million this year, after recognising $280 million such claims in the first quarter.
Clariant is scrapping a regular dividend as hunkers down to survive the COVID-19 crisis, the Swiss specialty chemicals maker said on Thursday, while still planning a special $1 billion payout from asset-sale proceeds, if they go through.
The Swiss maker of dental implants will slash hundreds of jobs after the COVID-19 crisis brought activity in the offices of dentists and orthodontists around the world largely to a standstill, forcing the company to retrench. The expected savings in 2021 will be about 30 million Swiss francs ($30.83 million).
Genentech announced positive results from a trial evaluating its dual immunotherapies, tiragolumab and Tecentriq, compared with Tecentriq alone, as the Swiss drugmaker gives a trial run to an experimental combination of medicines it hopes will improve treatment success rates for lung and other cancers that have remained frustratingly low.
The coronavirus that causes COVID-19 could become endemic like HIV, the World Health Organization said, warning against any attempt to predict how long it would keep circulating and calling for a “massive effort” to counter it.
Asia’s stock markets fell and gold hit a one-week high as worries about a second wave of coronavirus infections and a dour assessment of the way back from the head of the U.S. Federal Reserve dashed hopes for a quick recovery.
* Flughafen Zurich reported a 99% fall in passenger numbers in April compared with a year earlier.
* Relief Therapeutics said it got manufacturing validation for a drug from a partner that is being used in a coronavirus trial
* Polyphor announced the acceptance of an abstract at an upcoming virtual scientific program.
* Sunrise Communications cuts its 2020 sales forecast, citing uncertainty from the COVID-19 pandemic.
ALCON - SVB Leerink raises target price to $57 from $56
* Swiss April producer prices due at 0630 GMT
$1 = 0.9731 Swiss francs Reporting by Zurich newsroom and Berlin Speed Desk